Modifying the epigenome as a therapeutic strategy in myelodysplasia.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Hematology. American Society of Hematology. Education Program

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/ASHEDUCATION-2007.1.405PMID 18024658
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Code of Silence

  2008cited by this paper
• Clinical Trials and Observations

  2008cited by this paper
• RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis.

  2007cited by this paper
• Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

  2007cited by this paper
• Chromatin modifications and their function.

  2007cited by this paper
• Combination of 5-azacytidine (5-AZA) and valproic acid (VPA) in advanced solid cancers: A phase I study

  2007cited by this paper
• The epigenomics of cancer.

  2007cited by this paper
• An oral dosage formulation of azacitidine: A pilot pharmacokinetic study

  2007cited by this paper
• Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome

  2007cited by this paper
• Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.

  2007cited by this paper
• Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

  2007influential reference
• Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

  2006cited by this paper
• Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.

  2006cited by this paper
• Decitabine improves patient outcomes in myelodysplastic syndromes

  2006cited by this paper
• Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

  2006cited by this paper
• Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome

  2006cited by this paper
• G-CSF Increases Hematological Response among Patients with Myelodysplasia Treated with Azacitidine.

  2006cited by this paper
• Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study.

  2006cited by this paper
• Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

  2005cited by this paper
• Valproic Acid (VPA) Achieves High Response Rates in Patients with Low-Risk Myelodysplastic Syndromes.

  2005cited by this paper
• Histone Deacetylase Inhibitors: A Review of Their Clinical Status as Antineoplastic Agents

  2005cited by this paper
• Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.

  2005cited by this paper
• Rates of Infection and Bleeding Are Not Increased in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine Compared with Supportive Care.

  2005cited by this paper
• Azacitidine (Vidaza®) Treatment Response Assessed Using Three Alternative Dosing Schedules in Patients with Myelodysplastic Syndromes (MDS).

  2005cited by this paper
• Response Rates in Patients with Acute Myeloid Leukemia (AML), Treated with Azacitidine, Using WHO and International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS).

  2005cited by this paper
• Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

  2004influential reference
• Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.

  2004cited by this paper
• Histone deacetylases.

  2003cited by this paper
• Induction of Tumors in Mice by Genomic Hypomethylation

  2003cited by this paper
• Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.

  2002cited by this paper
• Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

  2002cited by this paper
• Deciphering the transcriptional histone acetylation code for a human gene.

  2002cited by this paper
• Code of silence.

  2001cited by this paper
• Methylation profiling in acute myeloid leukemia.

  2001cited by this paper
• Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

  2001cited by this paper
• A gene hypermethylation profile of human cancer.

  2001cited by this paper
• DNA methylation in health and disease

  2000cited by this paper
• Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.

  2000influential reference
• Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

  1999cited by this paper
• CpG island methylator phenotype in colorectal cancer.

  1999cited by this paper
• Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression.

  1998cited by this paper
• International scoring system for evaluating prognosis in myelodysplastic syndromes.

  1997cited by this paper
• Abnormal regional hypermethylation of the calcitonin gene in myelodysplastic syndromes.

  1995cited by this paper
• Cellular differentiation, cytidine analogs and DNA methylation.

  1980cited by this paper
• Chromatin Modifications and Their Function

  year unknowninfluential reference

• Artificial Intelligence Applications in Oral Cancer and Oral Dysplasia

  2024cites this paper
• Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management

  2020cites this paper
• Myeloid-Derived Suppressor Cells in Aged Humans

  2019cites this paper
• Genetics: Clues, Not Answers, to the Mysteries of Precision Medicine

  2018cites this paper
• Pathogenesis: Causation’s Shadow

  2014cites this paper
• The KDM2B- Let-7b -EZH2 Axis in Myelodysplastic Syndromes as a Target for Combined Epigenetic Therapy

  2014cites this paper
• Genome-Wide Integration on Transcription Factors, Histone Acetylation and Gene Expression Reveals Genes Co-Regulated by Histone Modification Patterns

  2011cites this paper
• Pharmacokinetic evaluation of decitabine for the treatment of leukemia

  2011cites this paper
• Cause of Death in Lower-Risk Myelodysplastic Syndromes

  2011cites this paper
• 28. The Myelodysplastic Syndromes

  2010cites this paper
• Prognosis of myelodysplastic syndromes.

  2010cites this paper
• Molecular Pathogenesis of Myelodysplastic Syndromes

  2010cites this paper
• The biology of myelodysplastic syndromes: unity despite heterogeneity

  2010cites this paper
• Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.

  2010cites this paper
• Current and Future Management Options for Myelodysplastic Syndromes

  2010cites this paper
• Progress in myelodysplastic syndromes.

  2009cites this paper
• Myelodysplastic syndrome: An update on diagnosis and therapy

  2009cites this paper
• Myelodysplastic syndrome: An update on diagnosis and therapy

  2008cites this paper
• Current treatment options and strategies for myelodysplastic syndromes

  2008cites this paper
• MEETING REPORT Meeting report: myelodysplastic syndromes at ASH 2007

  2008cites this paper
• Meeting report: myelodysplastic syndromes at ASH 2007

  2008cites this paper
• [Individualized management and therapy of myelodysplastic syndromes].

  2008cites this paper
• Die individualisierte Riskoeinschätzung und Therapieplanung bei myelodysplastischen Syndromen

  2008cites this paper